Mucolipidosis type IV (MLIV) is a rare autosomal recessive neurodegenerative disease caused by mutations of MCOLN1, which codes of mucolipin-1 a putative cation channel located in lysosomes. This research proposal aims to study the natural history of neurological and retinal manifestations of MLIV It also aims to increase awareness and improve diagnosis of MLIV among patients with cerebral palsy and those with retinal dystrophy of unknown cause. Over the past decade we have been studying prospectively various clinical and genetic aspects of MLIV in the only study of its kind. We hypothesize that MLIV is a combination of mostly developmental abnormality in the CMS and a degenerative retinal process. In this application we propose to 1) recruit known and newly diagnosed patients with MLIV and systematically study the neurological and retinal function over time. 2) Contact practicing physicians that take care of cerebral palsy patients and those with retinal dystrophy to increased awareness and improve diagnosis of MLIV. Based on our experience, we believe that many MLIV patients go undiagnosed. This project will help characterize and quantify the clinical abnormalities of MLIV and thus help define a patient population and outcome measures for future clinical trials.
Known and newly diagnosed patients with MLIV will be studied over time for neurological and retinal function. Practicing physicians that take care of cerebral palsy patients and those with retinal dystrophy will be contacted to increase awareness and improve diagnosis of MLIV as many may go undiagnosed. This study will help characterize and quantify the clinical abnormalities of MLIV and provide outcome measures for future clinical trials.
|Mauer, Michael; Glynn, Emily; Svarstad, Einar et al. (2014) Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLoS One 9:e112188|
|Rumsey, Robin K; Rudser, Kyle; Delaney, Kathleen et al. (2014) Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA. J Pediatr 164:1147-1151.e1|
|Schiffmann, Raphael; Forni, Sabrina; Swift, Caren et al. (2014) Risk of death in heart disease is associated with elevated urinary globotriaosylceramide. J Am Heart Assoc 3:e000394|
|Polgreen, Lynda E; Thomas, William; Fung, Ellen et al. (2014) Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI. J Clin Densitom 17:200-6|
|Polgreen, Lynda E; Thomas, William; Orchard, Paul J et al. (2014) Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome. Mol Genet Metab 111:101-6|
|Stevenson, David A; Rudser, Kyle; Kunin-Batson, Alicia et al. (2014) Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. J Pediatr Rehabil Med 7:159-65|
|Prater, Sean N; Banugaria, Suhrad G; Morgan, Claire et al. (2014) Letter to the Editors: Concerning "CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al. J Inherit Metab Dis 37:141-3|
|Schiffmann, Raphael; Mayfield, Joan; Swift, Caren et al. (2014) Quantitative neuroimaging in mucolipidosis type IV. Mol Genet Metab 111:147-51|
|Wang, Raymond Y; Braunlin, Elizabeth A; Rudser, Kyle D et al. (2014) Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness. Mol Genet Metab 111:128-32|
|Ahmed, Alia; Whitley, Chester B; Cooksley, Renee et al. (2014) Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the *-L-iduronidase gene in Hurler-Scheie syndrome. Mol Genet Metab 111:123-7|
Showing the most recent 10 out of 34 publications